ENTA - NASDAQ

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.

ENTAยทNASDAQ

$12.03

-6.6%
HealthcareBiotechnology

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$279.30M
EPS-3.8400
P/E Ratio-3.12
Earnings Date08/10/2026
Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. Fair Value Envelope

ENTA ยท NASDAQ

Our analysis suggests that ENTA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.03, this represents a potential HIDDEN relative to our calculated worth for Enanta Pharmaceuticals, Inc..

HIDDEN
Intrinsic Value
Current Price: $12.03

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$4.7B
+ Cash & Equivalents$32.3M
Firm Value-$4.7B
- Debt$201.1M
Equity Value-$4.9B
/ Shares Outstanding21,377,357B
DCF Value-$228
OVERVALUED BY 1997%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$32.1M
-$53.6M
-$89.3M
-$149.0M
-$248.4M
-$414.1M
-$690.5M
-$1.2B
-$1.9B
-$3.2B
Maintenance CapEx
-$4.3M
-$7.2M
-$12.0M
-$19.9M
-$33.2M
-$55.4M
-$92.4M
-$154.1M
-$256.9M
-$428.4M
Owner Earnings
-$36.4M
-$60.8M
-$101.3M
-$168.9M
-$281.6M
-$469.6M
-$782.9M
-$1.3B
-$2.2B
-$3.6B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$33.7M
-$52.1M
-$80.4M
-$124.1M
-$191.7M
-$295.9M
-$456.8M
-$705.3M
-$1.1B
-$1.7B
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your ENTA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.